RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials, Inc. (Worldwide), a full-service, midsize, global contract research organization (CRO), announced today that Emile Youssef, MD, PhD, has joined as vice president, oncology scientific solutions. This announcement comes one month after the appointment of Clare Wallis, senior vice president, oncology, as Worldwide continues to invest in helping sponsors achieve breakthroughs for cancer patients with its rapidly growing team of specialized experts.
Youssef brings 30 years of global, multidisciplinary experience to Worldwide with rich expertise in oncology clinical research, pharmaceutical development and academia. In addition to his post-doctoral work at the University of Texas MD Anderson Cancer Center, he spent more than 10 years in academia as a principal investigator in oncology. Following that, Youssef led a variety of critical functions for leading pharmaceutical sponsors Novartis, Eisai, Celgene and Bayer from international oncology early clinical development and proof-of-concept studies to medical affairs. He is also a thought leader in immune-oncology development who has published more than 20 peer-reviewed papers across clinical cancer journals while holding global hematology and oncology society memberships in America, Europe and Japan.
“Every clinical trial is an opportunity to meaningfully impact the lives of cancer patients with innovative treatments that improve prognoses,” said Youssef. “That’s why I’ve dedicated my life’s work to oncology and gaining expertise across stages of therapeutic development from early clinical research to proof-of-concept trials. I firmly believe that a multidisciplinary approach is vital to help more patients and their families.”
Youssef’s interconnected perspective mirrors medicine’s growing global and collaborative nature. This month, more than 16,000[i] oncology clinical trials are actively recruiting patients, and many are targeting a small subset of patients to match trial needs. To speed recruitment and ensure success in this competitive landscape, a global network of oncology centers, trial sites and professionals who are knowledgeable about unique technology under development and increasingly refined patient phenotypes to address market requirements are necessary.
“Worldwide continues to deliberately grow our team of oncology experts to meet sponsors’ demand for a CRO with the specialized expertise, personalized attention and global infrastructure at the ready to help them with even their most challenging trials,” said Peter Benton, president and chief operating officer, Worldwide Clinical Trials. “Dr. Youssef’s expansive global background and well-rounded experiences across academia, pharmaceutical development and clinical trials provide our customers with a unique, holistic viewpoint. It’s the direct access to global experts like him, at the moments when it matters most, that make Worldwide’s sponsor experience unlike any other.”
Learn about Emile Youssef, MD, PhD, and Worldwide’s growing team of oncology experts who are out to improve the CRO experience. And, if you are interested in joining a passionate and collaborative team that is valued and supported by company leadership, committed to operational excellence, and open to invention and innovation, Worldwide is hiring.
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,900 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services.
With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiometabolic, general medicine, oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit http://www.worldwide.com.
